CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...
Cambridge-based Fulcrum Therapeutics said it will aim to launch a large clinical trial in the second half of 2026 to prove ...
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) ...
News-Medical.Net on MSN
Timing of genetic mutation dictates childhood leukemia aggressiveness
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...
Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
The genetically engineered food is also protein packed and sustainable, say scientists. Chinese researchers used gene-editing ...
Penn Medicine shows how sustained research investment drives innovation, economic growth, and global health breakthroughs.
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...
Almost two thirds of patients with T-cell acute lymphoblastic leukaemia involved in a clinical trial of the treatment are now ...
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results